Display options
Cite
Ashby C, Tytarenko RG, Wang Y, et al. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of . Oncotarget. 2019;10(7):732-737doi: 10.18632/oncotarget.26589.
Ashby, C., Tytarenko, R. G., Wang, Y., Weinhold, N., Johnson, S. K., Bauer, M., Wardell, C. P., Schinke, C., Thanendrarajan, S., Zangari, M., van Rhee, F., Davies, F. E., Sawyer, J. R., Morgan, G. J., & Walker, B. A. (2019). Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of . Oncotarget, 10(7), 732-737. https://doi.org/10.18632/oncotarget.26589
Ashby, Cody, et al. "Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of ." Oncotarget vol. 10,7 (2019): 732-737. doi: https://doi.org/10.18632/oncotarget.26589
Ashby C, Tytarenko RG, Wang Y, Weinhold N, Johnson SK, Bauer M, Wardell CP, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Davies FE, Sawyer JR, Morgan GJ, Walker BA. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of . Oncotarget. 2019 Jan 22;10(7):732-737. doi: 10.18632/oncotarget.26589. eCollection 2019 Jan 22. PMID: 30774775; PMCID: PMC6366829.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2019 Jan 22;10(7):732-737. doi: 10.18632/oncotarget.26589. eCollection 2019 Jan 22.

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of .

Oncotarget

Cody Ashby, Ruslana G Tytarenko, Yan Wang, Niels Weinhold, Sarah K Johnson, Michael Bauer, Christopher P Wardell, Carolina Schinke, Sharmilan Thanendrarajan, Mauricio Zangari, Frits van Rhee, Faith E Davies, Jeffrey R Sawyer, Gareth J Morgan, Brian A Walker

Affiliations

  1. Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  2. Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

PMID: 30774775 PMCID: PMC6366829 DOI: 10.18632/oncotarget.26589

Abstract

Hyperhaploid multiple myeloma is a rare numerical aberration group defined by a range of 24-34 chromosomes, which is associated with a poor prognosis with a 5-year survival rate of 23%. Hyperhaploid patient samples (n=8) were sequenced and copy number and mutations identified. Samples had a median of 13 monosomies (range 12-14), which in general were those not associated with trisomies in hyperdiploid samples. The chromosomes traditionally trisomic in hyperdiploid myeloma were disomic in hyperhaploid myeloma with retention of heterodisomy. We examined the hyperhaploid samples for frequently mutated genes and found that 8/8 (100%) hyperhaploid samples had a mutation in

Keywords: TP53; bi-allelic; double-hit; myeloma; survival

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.

References

  1. Cancer Cell. 2007 Aug;12(2):115-30 - PubMed
  2. Cancer Cell. 2007 Aug;12(2):131-44 - PubMed
  3. Blood. 2010 Oct 14;116(15):e56-65 - PubMed
  4. Genes Chromosomes Cancer. 2012 Jun;51(6):536-44 - PubMed
  5. Nat Rev Cancer. 2012 Apr 12;12(5):335-48 - PubMed
  6. Cancer Genet. 2012 Jul-Aug;205(7-8):414-8 - PubMed
  7. Neoplasia. 2012 Sep;14(9):807-12 - PubMed
  8. Blood. 2015 Jan 29;125(5):831-40 - PubMed
  9. Cancer Genet. 2016 Jun;209(6):278-81 - PubMed
  10. Blood. 2016 Sep 29;128(13):1735-44 - PubMed
  11. Leukemia. 2017 Mar;31(3):637-644 - PubMed
  12. Blood Cancer J. 2017 Feb 24;7(2):e535 - PubMed
  13. Haematologica. 2017 Sep;102(9):e364-e367 - PubMed
  14. Leukemia. 2018 Nov;32(11):2435-2444 - PubMed
  15. Methods Mol Biol. 2018;1792:71-95 - PubMed
  16. Blood. 2018 Aug 9;132(6):587-597 - PubMed
  17. Leukemia. 2019 Jan;33(1):159-170 - PubMed

Publication Types